BiotechTube

Debamestrocel - MSC-NTF (NurOwn) + Placebo

Phase 3Recruiting
0 views this week 0 watching💤 Quiet🧠Featured in Neuroscience Pipeline Watch
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Amyotrophic Lateral Sclerosis (ALS)

Conditions

Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis

Trial Timeline

Jun 30, 2025 → May 1, 2029

NCT ID
NCT06973629

About Debamestrocel - MSC-NTF (NurOwn) + Placebo

Debamestrocel - MSC-NTF (NurOwn) + Placebo is a phase 3 stage product being developed by BrainStorm Cell Therapeutics for Amyotrophic Lateral Sclerosis (ALS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06973629. Target conditions include Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis.

What happened to similar drugs?

2 of 17 similar drugs in Amyotrophic Lateral Sclerosis (ALS) were approved

Approved (2) Terminated (4) Active (11)
🔄methylcobalamin + saline solutionEisaiPhase 3
🔄Olesoxime + Placebo Comparator + RiluzoleRochePhase 3
✅RiluzoleSanofiApproved
🔄Tofersen + PlaceboBiogenPhase 3
🔄Tofersen + PlaceboBiogenPhase 3
❌DexpramipexoleBiogenPhase 3
✅TofersenBiogenApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06973629Phase 3Recruiting

Competing Products

20 competing products in Amyotrophic Lateral Sclerosis (ALS)

See all competitors
ProductCompanyStageHype Score
AL001 + PlaceboAlectorPhase 2
17
89Zr-DFO-AP-101Eli LillyPhase 1
33
Reldesemtiv + PlaceboAstellas PharmaPhase 2
35
Perampanel + Placebo Oral TabletEisaiPre-clinical
18
E0302 (mecobalamin)EisaiPhase 2/3
38
E0302 (mecobalamin) + E0302 (mecobalamin) + PlaceboEisaiPhase 2/3
38
methylcobalamin + saline solutionEisaiPhase 3
40
ONO-2506POOno PharmaceuticalPhase 2
35
ONO-2506PO + ONO-2506POOno PharmaceuticalPhase 2
35
ZYIL1 capsules 25 mg and 50 mg Placebo + ZYIL1 capsules 50 mg and 25 mg Placebo + ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg + Matching placebo 25 mg and Matching placebo 50 mgZydus LifesciencesPhase 2
35
LY4256984 + PlaceboEli LillyPhase 1
36
TCH346NovartisPhase 2
35
VHB937NovartisPhase 2
39
TCH346NovartisPhase 2
35
TCH346NovartisPhase 2
35
BLZ945NovartisPhase 2
27
TRO19622RochePhase 2/3
38
Olesoxime + Placebo Comparator + RiluzoleRochePhase 3
40
Bosutinib (Phase 1 part) + Bosutinib (Phase 2 part)PfizerPhase 1/2
28
Celecoxib + Creatine + MinocyclinePfizerPhase 2
35